Case Commentaries

Case commentary: Bailey v GlaxoSmithKline UK Ltd [2017] EWHC 3195 (QB)

By 2018-02-06T13:43:00

funding signpost

Alison Kirby analyses this judgment in which the High Court has considered, for the first time, whether the Arkin cap - the principle that a funder’s potential liability for adverse costs will be limited to the amount of the funding provided - still fits.

 

 

This is premium content

In order to access this content you must be a member of the Dispute Resolution Section and logged in.

If you have not registered before, register now to gain access to this content. You must use the email associated with your section membership.

Log in

Not a Dispute Resolution Section Member?

Join now

if you require assistance with joining this section, email msadmin@lawsociety.org.uk or call us on 0207 320 5804